Figure 1

Induction therapy with Erlotinib (E) and Gemcitabine/Platinum (GP) in stage III NSCLC

Tobias R Overbeck*, Stefan HP Wenleder*, Bernhard C Danner, Wolfgang Körber, Karin Toepelt, Bernhard Hemmerlein, Christina Perske, Markus Falk, Markus Tiemann, Claudia Tomala, Elke Stitz and Frank Griesinger

Published: 28 January, 2021 | Volume 5 - Issue 1 | Pages: 001-018

jprr-aid1018-g001

Figure 1:

Consort diagram. Depicted are numbers of patients in pre-study and main study phase and reasons of exclusion for the main study.

Read Full Article HTML DOI: 10.29328/journal.jprr.1001018 Cite this Article Read Full Article PDF

More Images

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?